Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Treatment Outcomes of the Standardized Shorter MDR-TB Regimen Under Programmatic Setting: A Retrospective Study from a Tertiary Care Centre, India

Author(s): K.M.P Swathi, M. Somashekar, A. Chakraborty, R. Swapna*, J.S. Akshata and C. Nagaraja

Volume 18, Issue 1, 2022

Published on: 18 January, 2022

Page: [44 - 49] Pages: 6

DOI: 10.2174/1573398X17666211210143240

Price: $65

Abstract

Background: The shorter regimen was widely accepted and advocated for MDR-TB treatment compared tothe conventional longer regimen. Evaluating the performance of both regimens in a programmatic setting will help in tailoring the treatment regimen of MDR-TB.

Objectives: To estimate the duration of sputum smear conversion in the shorter MDR-TB regimen. 2. To compare the treatment outcomes of the shorter MDR-TB regimen with that of the longer conventional MDR regimen in a programmatic set up in India. 3. To estimate the adverse drug reactions in the shorter MDR-TB regimen.

Methods: A retrospective cross-sectional study was conducted on 320 patients enrolled under programmatic management of drug resistant tuberculosis (PMDT) from April 2017 to May 2019 at a nodal DRTB center and a tertiary care hospital in India. Demographic and clinical characteristics of those who received a shorter MDR-TB regimen were recorded. Treatment outcomes of both regimens were recorded. Treatment success is defined as ‘disease cured and treatment completed’, whereas treatment failure was considered when the treatment was either terminated or changed due to lack of bacteriological conversion at the end of an extended intensive phase or culture reversion in the continuation phase.

Results: The treatment success observed in the shorter MDR-TB regimen was 61.25%, which was significantly higher than the conventional longer regimen (p=0.0007). Treatment failures were higher with a shorter MDR-TB regimen (p=0.0001).

Conclusion: Treatment success with the shorter MDR-TB regimen though higher than the conventional regimen, is still way behind the target treatment success rate. Improving treatment adherence remains pivotal for achieving end TB targets.

Keywords: Alopecia, DRTB, PMDT, relapse, sputum conversion, treatment outcome.

« Previous Next »
Graphical Abstract

[1]
Nunn AJ, Phillips PPJ, Meredith SK, et al. STREAM Study Collaborators. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med 2019; 380(13): 1201-13.
[http://dx.doi.org/10.1056/NEJMoa1811867] [PMID: 30865791]
[2]
Goyal V, Kadam V, Narang P, Singh V. Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta- analysis. BMC Public Health 2017; 17(1): 817.
[http://dx.doi.org/10.1186/s12889-017-4779-5] [PMID: 29041901]
[3]
World Health Organization. Global tuberculosis report 2016.Geneva: WHO 2016.
[4]
World Health Organization. WHO Operational handbook on tuberculosis. Treatment of drug resistant tuberculosis. Geneva, Switzerland: World Health Organization 2020; p. 88.
[5]
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, Switzerland: World Health Organization 2019.
[6]
Guidelines on Programmatic management of Drug Resistant TB (PMDT) in India. Central TB division 2019; 195.
[7]
Guidelines on Programmatic management of Drug Resistant TB (PMDT) in India. Central TB division 2012; 190.
[8]
Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19(5): 517-24.
[http://dx.doi.org/10.5588/ijtld.14.0535] [PMID: 25868018]
[9]
Ahmad Khan F, Salim MAH, du Cros P, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 2017; 50(1): 1700061-1.
[http://dx.doi.org/10.1183/13993003.00061-2017] [PMID: 28751411]
[10]
Trébucq A, Schwoebel V, Kashongwe Z, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis 2018; 22(1): 17-25.
[http://dx.doi.org/10.5588/ijtld.17.0498] [PMID: 29149917]
[11]
Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18(10): 1188-94.
[http://dx.doi.org/10.5588/ijtld.13.0075] [PMID: 25216832]
[12]
Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182(5): 684-92.
[http://dx.doi.org/10.1164/rccm.201001-0077OC] [PMID: 20442432]
[13]
Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60(9): 1361-7.
[PMID: 25605283]
[14]
Dixit R, Quereshi D, Mathur S. Alopecia caused by isoniazid. J PharmacolPharmacother 2014; 5(2): 155-7.
[15]
Russom M, Berhe A, Hagos L. Second-line anti-tuberculosis drugs and risk of alopecia: A retrospective cohort study. Adv Pharmacoepidemiol Drug Saf 2018; 7: 224.
[http://dx.doi.org/10.4172/2167-1052.1000224]
[16]
Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J 2020; 55(3): 1901467.
[http://dx.doi.org/10.1183/13993003.01467-2019] [PMID: 31862767]

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy